Evidence map›Paper›PMID 40241895›Full record

ArticleFrontiers in medicine2025

Plasma methylated

Weiwei Zhu, Huifen Wang, Yudie Cai, Jun Lei, Jia Yu, Ang Li, Zujiang Yu

Abstract read
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Weiwei Zhu *Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Huifen Wang *Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yudie CaiDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jun LeiDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jia YuDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ang LiPrecision Medicine Center, Gene Hospital of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zujiang YuDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: DNA methylation carrying epigenetic aberrations could potentially serve as a non-invasive tool for revolutionizing cancer diagnosis and monitoring. Here, we comprehensively evaluated the diagnostic value of plasma methylated Methods: The level of Results: The methylation level of Conclusion: Together, we identified and validated a diagnostic model that incorporated methylated

Indexed as

DNA methylationearly diagnosishepatocellular carcinomaHIST1H3Gprognosis

Identifiers

PMID40241895
PMCPMC12000021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.